菊粉果聚糖对代谢综合征患者血脂、血糖影响的临床观察

发布时间：2018-05-27 15:11

  本文选题：菊粉果聚糖 + 代谢综合征　； 参考：《甘肃中医药大学》2016年硕士论文

【摘要】：目的:代谢综合征是各种心血管危险因素组成的临床综合征,其临床表现包括腹型肥胖、高脂血症、高血糖或糖尿病及高血压,其具体机制是胰岛素抵抗和炎症反应,其中肥胖是代谢综合征和胰岛素抵抗的最主要的危险因素。菊粉果聚糖是一种从植物根茎中提炼出的多聚果糖。既往研究显示,菊粉果聚糖有降低血脂、血糖的作用,并广泛用于食品添加剂,以代替脂质成分减少热量摄入。然而,其在代谢综合征患者中的作用研究较少。本项研究的目的是观察不同剂量菊粉果聚糖对代谢综合征患者血脂、血糖及体重指数的影响,旨在评价菊粉果聚糖在代谢综合征患者中的应用价值。方法:本项研究采用随机对照试验设计,连续选入2015年3月至7月就诊于甘肃省人民医院心内科的代谢综合征患者300例,随机分为3组,每组100例,A组[高剂量(20g/d)菊粉果聚糖治疗组],B组[低剂量(10g/d)菊粉果聚糖治疗组],C组(单纯饮食控制组),干预3个月,采集患者的基线资料,分别于入组时、治疗3月时收集所有患者清晨空腹血标本,比较三组患者干预前后体重指数、腹围、臀围、血脂、血糖、收缩压等指标。结果:三组患者基线资料无统计学差异。治疗前后3组患者体重指数及腹围、臀围无明显差异。经3个月治疗后,结果显示,菊粉果聚糖治疗组患者血清总胆固醇(3.61±1.10vs.3.73±0.81vs.4.65±1.17,P=0.038,P=0.022,P=0.031),血清甘油三酯水平(1.59±0.69vs.1.79±1.14vs.1.57±0.72,P=0.041,P=0.011,P=0.031),低密度脂蛋白(3.02±0.84vs.3.02±0.94vs.3.14±0.89 P=0.042,P=0.026,P=0.041),血糖(5.11±0.49vs.5.36±1.37 vs.5.35±0.98 P=0.041,P=0.031,P=0.021)及收缩压(126.72±11.98 vs.124.45±13.6 vs.130.36±19.50 P=0.033,P=0.034,P=0.015)水平低于单纯饮食控制组,高密度脂蛋白(1.30±0.22 vs.1.20±0.27vs.0.29±0.62 P=0.026,P=0.033,P=0.025)水平高于单纯饮食控制组。进一步分析显示,治疗前后A、B两组患者总胆固醇(A组:4.57±0.93vs.3.61±1.10,P=0.045;B组:4.85±1.46vs.3.73±0.81,P=0.049)、甘油三酯(A组:1.76±0.57vs.1.59±0.69,P=0.046;B组:1.94±1.12vs.1.79±1.14,P=0.048)、高密度脂蛋白(A组:0.28±0.33vs.1.30±0.22,P=0.036;B组:0.32±0.25vs.1.20±0.27,P=0.016)、低密度脂蛋白(A组:3.06±0.82vs.3.02±0.84,P=0.035;B组:3.04±0.88 vs.3.02±0.94,P=0.022)、血糖(A组:5.21±1.35vs.5.11±0.49,P=0.010;B组:5.39±0.90 vs.5.36±1.37,P=0.019).及收缩压(A组:130.72±11.20vs.130.72±11.20,P=0.021;B组:131.45±13.11vs.124.45±13.62,P=0.015)水平均有统计学差异。C组患者治疗前后血脂、血糖及收缩压无统计学差(P0.05)。治疗后A组与B组(P=0.008),B组与C组(P=0.002),A组与C(P=0.001)均有统计学差异。结论:服用菊粉可调节代谢综合征肥胖患者的血糖、血脂水平并对降低心血管疾病风险有潜在益处。
[Abstract]:Objective: metabolic syndrome is a clinical syndrome composed of various cardiovascular risk factors. Its clinical manifestations include abdominal obesity, hyperlipidemia, hyperglycemia or diabetes mellitus and hypertension. Obesity is the most important risk factor for metabolic syndrome and insulin resistance. Inulin is a polyfructose extracted from plant roots. Previous studies have shown that inulin can reduce blood lipids and blood sugar and is widely used as food additive to reduce calorie intake instead of lipids. However, its role in metabolic syndrome patients is less studied. The purpose of this study was to observe the effects of different doses of inulin on blood lipids, blood glucose and body mass index (BMI) in patients with metabolic syndrome, and to evaluate the value of inulin in patients with metabolic syndrome. Methods: a randomized controlled trial was used to select 300 patients with metabolic syndrome from March to July 2015 in Department of Cardiology, Gansu Provincial people's Hospital, and were randomly divided into 3 groups. Group A [high dose 20 g / d] group B [low dose 10 g / d] group C (diet control group, intervention 3 months), baseline data of patients were collected. Fasting blood samples of all patients were collected at 3 months after treatment. Body mass index, abdominal circumference, hip circumference, blood lipid, blood glucose and systolic blood pressure were compared before and after intervention. Results: there was no statistical difference in baseline data among the three groups. There was no significant difference in body mass index, abdominal circumference and hip circumference between the three groups before and after treatment. 缁，

本文编号：1942629